Our data raise the possibility of a beneficial effect of SGLT2 inhibitors in patients with prediabetes, mainly, those with a metabolic disease in order to prevent a progression to diabetes and a reduced cardiovascular risk. Here, SLC5A2 is linked to prediabetes syndrome.